canakinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4952 914613-48-2

Description:

MoleculeDescription

Synonyms:

  • canakinumab
  • ilaris
  • ACZ885
a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 2009 EMA
June 17, 2009 FDA NOVARTIS PHARMS
Sept. 26, 2011 PMDA Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 797.82 18.24 349 8107 103616 63376950
Haemophagocytic lymphohistiocytosis 306.55 18.24 95 8361 10532 63470034
Pyrexia 297.14 18.24 337 8119 470141 63010425
Incorrect dose administered 171.46 18.24 104 8352 59864 63420702
Serum ferritin increased 116.24 18.24 40 8416 6142 63474424
Serum amyloid A protein increased 114.42 18.24 22 8434 314 63480252
COVID-19 88.08 18.24 91 8365 113012 63367554
Illness 79.74 18.24 60 8396 48999 63431567
Clubbing 79.24 18.24 17 8439 429 63480137
Condition aggravated 70.43 18.24 161 8295 402056 63078510
Lymphadenopathy 62.41 18.24 47 8409 38411 63442155
Hepatosplenomegaly 53.39 18.24 18 8438 2596 63477970
C-reactive protein increased 51.09 18.24 63 8393 94644 63385922
Malaise 50.39 18.24 145 8311 415809 63064757
SARS-CoV-2 test positive 48.60 18.24 23 8433 8033 63472533
Symptom recurrence 47.22 18.24 15 8441 1795 63478771
Product use in unapproved indication 45.82 18.24 84 8372 178996 63301570
Concomitant disease aggravated 40.11 18.24 21 8435 9091 63471475
Drug reaction with eosinophilia and systemic symptoms 39.27 18.24 34 8422 33802 63446764
Epstein-Barr virus infection 36.71 18.24 19 8437 8031 63472535
Gastroenteritis 35.56 18.24 29 8427 26561 63454005
Product supply issue 35.50 18.24 12 8444 1743 63478823
Juvenile idiopathic arthritis 34.80 18.24 14 8442 3312 63477254
Pneumonia lipoid 34.72 18.24 7 8449 129 63480437
Blood lactate dehydrogenase increased 32.58 18.24 26 8430 23090 63457476
Tonsillitis 30.44 18.24 15 8441 5720 63474846
Blood creatine phosphokinase decreased 29.87 18.24 8 8448 525 63480041
Arthralgia 29.83 18.24 152 8304 569558 62911008
Cough 29.68 18.24 96 8360 292647 63187919
Rhinorrhoea 28.15 18.24 39 8417 65538 63415028
Oropharyngeal pain 27.59 18.24 47 8409 94440 63386126
Cellulitis staphylococcal 27.19 18.24 8 8448 740 63479826
Pharyngitis streptococcal 26.62 18.24 17 8439 10655 63469911
Influenza 25.28 18.24 49 8407 108673 63371893
Autoinflammatory disease 25.04 18.24 6 8450 251 63480315
Rash 24.18 18.24 142 8314 560729 62919837
Actinomycotic sepsis 23.96 18.24 5 8451 110 63480456
Familial cold autoinflammatory syndrome 23.77 18.24 3 8453 0 63480566
Abdominal pain 23.47 18.24 89 8367 293367 63187199
Cytopenia 22.96 18.24 16 8440 11585 63468981
Normal newborn 22.60 18.24 14 8442 8327 63472239
Infusion related reaction 22.59 18.24 3 8453 245518 63235048
Interleukin level increased 22.01 18.24 6 8450 421 63480145
Ileal ulcer 21.22 18.24 6 8450 482 63480084
Familial mediterranean fever 20.61 18.24 4 8452 60 63480506
Asteatosis 20.55 18.24 4 8452 61 63480505
Drug hypersensitivity 20.30 18.24 8 8448 310679 63169887
Focal nodular hyperplasia 20.29 18.24 6 8450 565 63480001
Drug intolerance 20.08 18.24 8 8448 308653 63171913
Amyloidosis 20.00 18.24 7 8449 1128 63479438
Syringe issue 19.82 18.24 9 8447 2860 63477706
Contraindicated product administered 19.22 18.24 3 8453 217645 63262921
Wrist deformity 19.00 18.24 8 8448 2122 63478444
Splenomegaly 18.90 18.24 14 8442 11143 63469423
Sputum abnormal 18.79 18.24 6 8450 730 63479836
Fall 18.62 18.24 15 8441 392319 63088247
Interstitial lung disease 18.33 18.24 31 8425 61877 63418689
Cryopyrin associated periodic syndrome 18.29 18.24 5 8451 355 63480211

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apparent death 1011.78 27.66 227 9215 3417 34944072
Diverticulitis 701.81 27.66 246 9196 19758 34927731
Joint swelling 481.41 27.66 260 9182 59630 34887859
Deep vein thrombosis 396.50 27.66 236 9206 65012 34882477
Inappropriate schedule of product administration 390.74 27.66 230 9212 62066 34885423
Pulmonary thrombosis 386.38 27.66 123 9319 7284 34940205
Red blood cell sedimentation rate increased 372.49 27.66 126 9316 9036 34938453
Pulmonary embolism 360.33 27.66 250 9192 89496 34857993
Terminal state 302.13 27.66 88 9354 3846 34943643
Renal failure 269.49 27.66 246 9196 130311 34817178
Pain 259.05 27.66 296 9146 204379 34743110
C-reactive protein abnormal 244.41 27.66 91 9351 8619 34938870
Thrombosis 182.10 27.66 132 9310 50326 34897163
C-reactive protein increased 178.31 27.66 134 9308 53964 34893525
Photosensitivity reaction 163.34 27.66 72 9370 10522 34936967
Intestinal sepsis 154.74 27.66 36 9406 635 34946854
Joint arthroplasty 154.67 27.66 38 9404 853 34946636
Haemophagocytic lymphohistiocytosis 146.37 27.66 71 9371 12902 34934587
Drug ineffective 132.67 27.66 342 9100 456409 34491080
Contraindicated product administered 112.85 27.66 71 9371 21410 34926079
Sepsis 104.52 27.66 172 9270 166389 34781100
Intentional product use issue 98.82 27.66 100 9342 59716 34887773
Herpes zoster 97.50 27.66 78 9364 34321 34913168
Arthropathy 89.28 27.66 67 9375 26840 34920649
Stent placement 86.35 27.66 37 9405 5041 34942448
Stomatitis 85.08 27.66 79 9363 42435 34905054
Interstitial lung disease 82.94 27.66 95 9347 65187 34882302
Pyrexia 80.79 27.66 234 9208 332779 34614710
Knee arthroplasty 75.77 27.66 38 9404 7406 34940083
Feeling abnormal 73.62 27.66 88 9354 63147 34884342
Incorrect dose administered 72.90 27.66 71 9371 40444 34907045
Serum amyloid A protein increased 72.72 27.66 13 9429 53 34947436
Illness 71.73 27.66 45 9397 13484 34934005
Urticaria 69.66 27.66 85 9357 62292 34885197
Drug intolerance 66.23 27.66 81 9361 59489 34888000
Drug interaction 46.30 27.66 4 9438 225942 34721547
Myocardial infarction 44.71 27.66 100 9342 120985 34826504
Juvenile idiopathic arthritis 43.06 27.66 17 9425 1880 34945609
Off label use 41.25 27.66 222 9220 419302 34528187
Toxicity to various agents 39.83 27.66 4 9438 200358 34747131
Drug hypersensitivity 38.50 27.66 74 9368 80455 34867034
Tonsillitis 35.86 27.66 16 9426 2400 34945089
Nausea 33.24 27.66 26 9416 339882 34607607
Dyspnoea 33.01 27.66 32 9410 376750 34570739
Hypotension 30.36 27.66 11 9431 221638 34725851
Concomitant disease aggravated 30.30 27.66 19 9423 5682 34941807

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 594.72 20.03 337 13372 133291 79597388
Apparent death 421.57 20.03 98 13611 2767 79727912
Pulmonary thrombosis 308.63 20.03 105 13604 12066 79718613
Haemophagocytic lymphohistiocytosis 306.97 20.03 122 13587 21715 79708964
Terminal state 280.98 20.03 79 13630 4810 79725869
Pyrexia 276.85 20.03 449 13260 678260 79052419
Red blood cell sedimentation rate increased 223.09 20.03 123 13586 45819 79684860
Diverticulitis 212.15 20.03 119 13590 45817 79684862
Incorrect dose administered 188.21 20.03 133 13576 76497 79654182
C-reactive protein increased 179.03 20.03 160 13549 128867 79601812
Serum amyloid A protein increased 161.29 20.03 31 13678 335 79730344
C-reactive protein abnormal 130.54 20.03 89 13620 48278 79682401
Thrombosis 130.05 20.03 111 13598 83989 79646690
Intestinal sepsis 128.24 20.03 30 13679 869 79729810
Photosensitivity reaction 114.84 20.03 61 13648 21066 79709613
Illness 101.05 20.03 75 13634 46436 79684243
Pulmonary embolism 95.64 20.03 132 13577 171522 79559157
Sepsis 95.32 20.03 168 13541 269260 79461419
Joint arthroplasty 95.12 20.03 30 13679 2710 79727969
Deep vein thrombosis 89.38 20.03 107 13602 120812 79609867
Interstitial lung disease 78.91 20.03 97 13612 112503 79618176
Serum ferritin increased 78.87 20.03 37 13672 9810 79720869
COVID-19 74.27 20.03 112 13597 157562 79573117
Renal failure 73.19 20.03 127 13582 200841 79529838
Stent placement 66.49 20.03 29 13680 6491 79724188
Herpes zoster 64.90 20.03 80 13629 93003 79637676
Urticaria 63.50 20.03 114 13595 185087 79545592
Joint swelling 62.61 20.03 147 13562 288499 79442180
Juvenile idiopathic arthritis 61.31 20.03 25 13684 4738 79725941
Tonsillitis 56.16 20.03 26 13683 6688 79723991
Concomitant disease aggravated 55.06 20.03 32 13677 13135 79717544
Symptom recurrence 54.87 20.03 19 13690 2295 79728384
Drug interaction 46.01 20.03 8 13701 415175 79315504
Product use in unapproved indication 45.27 20.03 119 13590 250240 79480439
Lymphadenopathy 44.11 20.03 50 13659 53197 79677482
Feeling abnormal 43.46 20.03 89 13620 159110 79571569
Pain 43.15 20.03 236 13473 703566 79027113
Condition aggravated 42.90 20.03 185 13524 500939 79229740
SARS-CoV-2 test positive 42.54 20.03 26 13683 11690 79718989
Autoinflammatory disease 41.96 20.03 10 13699 314 79730365
Product supply issue 41.64 20.03 15 13694 2033 79728646
Toxicity to various agents 40.87 20.03 11 13698 421529 79309150
Gastroenteritis 38.94 20.03 38 13671 34044 79696635
Clubbing 38.56 20.03 11 13698 704 79729975
Oropharyngeal pain 37.03 20.03 67 13642 109286 79621393
Pneumonia 36.23 20.03 215 13494 660031 79070648
Hepatosplenomegaly 34.32 20.03 18 13691 6051 79724628
Myocardial infarction 33.75 20.03 88 13621 184041 79546638
Stomatitis 32.03 20.03 75 13634 146682 79583997
Rhinorrhoea 31.54 20.03 51 13658 76023 79654656
Familial mediterranean fever 30.72 20.03 7 13702 180 79730499
Influenza 30.23 20.03 68 13641 129538 79601141
Arthralgia 29.29 20.03 183 13526 571620 79159059
Upper respiratory tract inflammation 28.77 20.03 14 13695 4021 79726658
Cellulitis 28.60 20.03 60 13649 109000 79621679
Asteatosis 28.58 20.03 6 13703 104 79730575
Nausea 27.85 20.03 79 13630 957117 78773562
Growth retardation 27.78 20.03 11 13698 1932 79728747
Intentional product use issue 27.15 20.03 72 13637 152040 79578639
Otitis media 25.95 20.03 15 13694 6091 79724588
Dyspnoea 25.46 20.03 70 13639 856955 78873724
Hypotension 25.40 20.03 23 13686 440294 79290385
Cellulitis staphylococcal 25.39 20.03 9 13700 1164 79729515
Hyperferritinaemia 25.27 20.03 8 13701 731 79729948
Cough 24.43 20.03 126 13583 366663 79364016
Fall 24.16 20.03 29 13680 487600 79243079
Blood creatine phosphokinase decreased 23.11 20.03 8 13701 965 79729714
Actinomycotic sepsis 23.05 20.03 5 13704 102 79730577
Pharyngitis streptococcal 22.63 20.03 17 13692 10697 79719982
Upper respiratory tract infection 22.57 20.03 49 13660 91119 79639560
Drug ineffective 21.79 20.03 282 13427 1080631 78650048
Haemoglobin decreased 20.49 20.03 84 13625 222035 79508644
Secondary adrenocortical insufficiency 20.12 20.03 10 13699 3004 79727675

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Familial Mediterranean fever indication 12579009 DOID:2987
Articular gout indication 48440001 DOID:13189
Deficiency of mevalonate kinase indication 124327008 DOID:0050452
Systemic onset juvenile chronic arthritis indication 201796004
TNF receptor-associated periodic fever syndrome (TRAPS) indication 403833009
Cryopyrin associated periodic syndrome indication 430079001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-1 beta Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D09315 KEGG_DRUG
4028805 VUID
N0000178497 NUI
4028805 VANDF
CHEMBL1201834 ChEMBL_ID
C541220 MESH_SUPPLEMENTAL_RECORD_UI
6773 IUPHAR_LIGAND_ID
DB06168 DRUGBANK_ID
853491 RXNORM
165731 MMSL
26503 MMSL
d07451 MMSL
013212 NDDF
698091001 SNOMEDCT_US
703376008 SNOMEDCT_US
C2718773 UMLSCUI
8836 INN_ID
37CQ2C7X93 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ilaris HUMAN PRESCRIPTION DRUG LABEL 1 0078-0734 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 31 sections
Ilaris HUMAN PRESCRIPTION DRUG LABEL 1 0078-0734 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 31 sections
Ilaris HUMAN PRESCRIPTION DRUG LABEL 1 0078-0734 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 31 sections